Tirzepatide trial shows additional 21.1% weight loss following intensive lifestyle intervention

Oct. 17, 2023—A Vanderbilt clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were overweight with weight-related comorbidities, excluding Type 2 diabetes.

Read more